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The β2-adrenergic receptor (β2AR) has been a model system for under-
standing regulatory mechanisms of G-protein–coupled receptor (GPCR)
actions and plays a significant role in cardiovascular and pulmonary
diseases. Because all known β-adrenergic receptor drugs target the
orthosteric binding site of the receptor, we set out to isolate allosteric
ligands for this receptor by panning DNA-encoded small-molecule li-
braries comprising 190 million distinct compounds against purified hu-
man β2AR. Here, we report the discovery of a small-molecule negative
allosteric modulator (antagonist), compound 15 [([4-((2S)-3-(((S)-3-
(3-bromophenyl)-1-(methylamino)-1-oxopropan-2-yl)amino)-2-(2-
cyclohexyl-2-phenylacetamido)-3-oxopropyl)benzamide], exhibiting
a unique chemotype and lowmicromolar affinity for the β2AR. Binding
of 15 to the receptor cooperatively enhances orthosteric inverse agonist
binding while negatively modulating binding of orthosteric agonists.
Studies with a specific antibody that binds to an intracellular region of
the β2AR suggest that 15 binds in proximity to the G-protein binding
site on the cytosolic surface of the β2AR. In cell-signaling studies, 15
inhibits cAMP production through the β2AR, but not that mediated by
other Gs-coupled receptors. Compound 15 also similarly inhibits
β-arrestin recruitment to the activated β2AR. This study presents an
allosteric small-molecule ligand for the β2AR and introduces a broadly
applicable method for screening DNA-encoded small-molecule libraries
against purified GPCR targets. Importantly, such an approach could
facilitate the discovery of GPCR drugs with tailored allosteric effects.
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G-protein–coupled receptors (GPCRs), also known as seventransmembrane receptors, represent the largest family of
cellular receptors and the most common therapeutic drug tar-
gets. Accordingly, GPCRs are the subject of intensive research,
both in academia and the pharmaceutical industry, aimed at
elucidating their structures, detailed mechanisms of action, and
discovery of novel ligands with therapeutic potential (1–3). To
date, the overwhelming majority of GPCR drugs target the
orthosteric site on the receptors. This is the binding site of endog-
enous ligands, which generally faces the extracellular surface of the
receptor (4, 5). However, in recent years, functionally active allo-
steric ligands, which bind outside the orthosteric site, have also been
discovered. Allosteric ligands that augment or reduce the binding
affinity and/or functional responses of orthosteric ligands are re-
ferred to as positive or negative allosteric modulators (PAMs or
NAMs), respectively (5). Such allosteric ligands hold great thera-
peutic promise due to their enhanced selectivity among receptor
subtypes compared with orthosteric drugs targeting the same sub-
type. The first approved allosteric drugs for GPCRs target che-
mokine CCR5 (6) and calcium-sensing receptors (7) to treat HIV
infections and hyperparathyroidism, respectively, with many more
modulators in preclinical development. Allosteric modulators also
have great utility as tool compounds in biophysical studies as they
are able to lock receptors into specific conformations by virtue of
their cooperative interactions with orthosteric ligands (4, 5).
In the past, screening for GPCR ligands, either allosteric or
orthosteric, has been cumbersome and labor-intensive. Such
screens have generally been based on the functional ability of
compounds to either stimulate or block receptor-mediated activ-
ities in whole-cell–based settings (8). A more rapid and efficient
approach is to use interaction-based methods for initial screening
wherein large libraries of molecules are panned against the target
receptor. However, until recently, such libraries have consisted
only of macromolecules such as phage-displayed antibodies (9, 10)
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or RNA aptamers (11). Another approach, which has not yet been
widely applied, is screening of DNA-encoded small-molecule li-
braries (DELs). In this approach, remarkably large combinatorial
libraries consisting of up to billions of small-molecule compounds
are displayed on DNA fragments that serve as barcodes for their
subsequent identification (12, 13). In the past few years, application
of the DEL screening technology for soluble proteins has produced
inhibitors against cancer and immune disorders and against thera-
peutic targets. These are protein kinases such as Src, MK2, Akt3,
Pim1, Aurora A kinase, p38 mitogen-activated protein (MAP) ki-
nase, and antiapoptotic protein Bcl-xL (14, 15). Expanding such
technology to GPCRs has the potential to yield both orthosteric and
allosteric ligands. However, its application to GPCR screening has
been challenging, largely because of difficulties associated with
preparing appropriate receptor targets as well as the membrane-
bound nature of the receptors, which can lead to nonspecific in-
teractions. To date, identification of a compound that inhibits the
NK3 tachykinin receptor by screening against the receptor expressed
in whole cells represents the only successful application of DEL
technology against GPCRs (16).
The β2-adrenergic receptor (β2AR) has served as the model
system for molecular studies of ligand-binding GPCRs for over 40 y
(1) and plays a significant role in cardiovascular and pulmonary
diseases. So-called “β-blockers,” which are orthosteric antagonists
of the receptor, are mainstays of cardiovascular medicines used
to treat a wide variety of illnesses (17–19). On the other hand,
β-agonists have proven very effective against asthma (20). How-
ever, all known β-adrenergic ligands act orthosterically; thus, it is
possible that allosteric modulators would possess enhanced ther-
apeutic efficacy, selectivity, or even unique therapeutic properties
such as signaling bias. Such ligands would also facilitate the iso-
lation and characterization of specific receptor conformations for
biophysical studies. Accordingly, here we set out to isolate allo-
steric ligands for the β2AR using DELs. We report isolation of a
small-molecule negative allosteric modulator (antagonist) for the
β2AR and provide a detailed characterization of its pharmaco-
logical properties and interaction with the receptor.
Results
Isolation of Compound 15 from DELs. To identify unique chemotypes
that bind at structurally relevant sites on the surface of β2AR, we
screened DELs against purified, unliganded β2AR maintained in
the detergent n-dodecyl-β-D-maltoside (DDM) (Fig. 1A and Fig.
S1). A similar beads-only selection was performed in parallel as a
control. In total, we screened three libraries together containing
approximately a total of 190 million unique compounds synthe-
sized using a DNA-tagged, split-and-pool combinatorial chemical
synthesis approach (Chemetics; Nuevolution). In each library,
∼5 × 1013 molecules in total were used as input, and 1–7 × 107
molecules remained after screening. Relative quantification of the
recovered compounds was achieved by a combination of PCR
amplification and next-generation sequencing of elutedDNA barcodes,
followed by computational decoding approaches. To refine the out-
put and eliminate potential nonspecific binders, compounds that
displayed less than a 260- to 470-fold increase in frequency from
baseline as well as those that were observed in bead-only con-
trol selections were filtered from the dataset, leaving a total of 394
potential β2AR binders for further analysis (Table S1). These com-
pounds were then clustered based on their structural similarity, and
16 putative hits were selected as representatives for these clusters.
DNA-tagged versions of these 16 hits were resynthesized and
screened individually to evaluate their influence on the binding affinity
of orthosteric agonists in radioligand binding assays with membranes
obtained from β2AR-overexpressing cells. One compound [4-((2S)-3-
(((S)-3-(3-bromophenyl)-1-(methylamino)-1-oxopropan-2-yl)amino)-2-
(2-cyclohexyl-2-phenylacetamido)-3-oxopropyl)benzamide], desig-
nated as compound “15” (Fig. 1B), markedly decreased orthosteric
agonist binding to the receptor and was thus selected for further
characterization.
Characterization of Compound 15 for Its Binding to the β2AR.To further
characterize the pharmacological properties of 15, we synthe-
sized it in its DNA-free form (Fig. 1B). We first performed
competition binding experiments with the radioiodinated an-
tagonist cyanopindolol (125I-CYP) to evaluate the influence of
15 on the binding ability of orthosteric ligands to the β2AR recon-
stituted into high-density lipoprotein (HDL) (also known as nanodisc)
particles (21). We found that, although 15 had little to no influence on
binding of 125I-CYP, which is a neutral orthosteric antagonist of the
β2AR, it robustly decreased the binding affinity of the agonist iso-
proterenol for the receptor in a dose-dependent fashion (Fig. 2A).
Compound 15 caused the isoproterenol competition curve to shift to
the right by close to one log (ninefold) at the maximal concentration
tested. The half-maximal concentration of 15 for this shift was
∼1.9 μM (Fig. 2B). On the other hand, when the inverse agonist [3H]-
ICI-118,551 was used as an orthosteric ligand tracer, 15 significantly
increased (18± 1%max) its binding to the β2AR in a dose-dependent
manner (Fig. 2C) with an EC50 value of 0.48 μM, which is close to that
obtained in Fig. 2B (1.9 μM). This reflects positive cooperativity be-
tween 15 and the orthosteric antagonist [3H]-ICI-118,551 for binding
to the receptor. To validate the direct binding of 15 to the β2AR, we
performed isothermal titration calorimetry (ITC). By this technique,
we found that the equilibrium dissociation constant (Kd) of 15 for the
receptor is 1.7 ± 0.8 μM, and the stoichiometry of the interaction is 1,
suggesting that 15 binds to one site on the β2AR (Fig. 2D). The Kd
value obtained by ITC is in good agreement with the half-maximal
concentration of the shift obtained in the radioligand competition
binding experiment (Fig. 2B) as well as the EC50 value obtained from
the 15 titration curve for [3H]-ICI-118,551 binding (Fig. 2C).
To further confirm that 15 favors an inactive conformational state
of the receptor, we assessed the extent of binding of an inactive
conformation-specific β2AR single domain antibody [nanobody-60
(Nb60)] that binds to an intracellular region of the receptor (10, 22).
Contrary to the positive cooperativity predicted to occur between a
negative allosteric modulator and Nb60 (22), we found a decrease
in Nb60 binding to the receptor in the presence of 15 (Fig. 2E). This
suggests that 15 competes with Nb60 for binding to the receptor,
and thus that their binding sites at least partially overlap, indicating
that 15 binds to an intracellular region of the β2AR.
It has been well appreciated that allosteric transducers such as
heterotrimeric G proteins or β-arrestins promote high-affinity
agonist binding (10, 23, 24). We also observed that 15 inhibited the
high-affinity binding of a radiolabeled β2AR-agonist, [3H](R,R′)-4-
methoxyfenoterol (3H-Fen) (25) that is promoted by either het-
erotrimeric Gs protein or β-arrestin1 (Fig. 2F). This finding also
suggests that 15 negatively modulates activation of the β2AR by
agonists. Furthermore, the dose-dependent effects of 15 in 3H-Fen
binding assays conducted in the presence of either G protein or
A B
Fig. 1. Screening of the DEL and the chemical structure of 15. (A) Schematic
illustration of the screening of a DNA-encoded compound library. DNA-
encoded library molecules, synthesized using a DNA-tagged, split-and-pool
combinatorial chemical synthesis approach, were mixed with a target (pu-
rified β2AR) immobilized on a matrix. Target binding (active) molecules were
collected through affinity-based selection, and the encoding DNA tags were
sequenced to identify the binding molecules. (B) Compound 15 is composed
of three building blocks: methybenzamide (green), bromo-benzyl (red), and
cyclohexylmethyl-benzene (blue). The amide backbone is shown in black.
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β-arrestin were similar to each other (Fig. 2G). We used Fab30,
which stabilizes an active conformation of β-arrestin1 (26, 27), to
enhance the weak high-affinity 3H-Fen binding signal induced by
β-arrestin to levels comparable to those observed with G protein.
The EC50 values obtained from the 15 dose–response curves for
the two transducer-promoted signals were comparable (2.8 vs.
2.2 μM, respectively, for G protein and β-arrestin; Fig. 2G). This
suggests that 15 displays no strong “bias” between its inhibitory
activities in the two transducer-induced high-affinity 3H-Fen
binding signals. The EC50 values of 15 obtained here (Fig. 2G) are
also in good agreement with its Kd measured by ITC (Fig. 2D).
Taken all together, the results in Fig. 2 show that 15 behaves as a
negative allosteric modulator for the β2AR, and suggest that it
binds at the cytoplasmic surface of the receptor.
Functional Modulation of β2AR Activity by Compound 15. Next, we
investigated the effects of 15 on β2AR function in cells by
measuring G-protein–mediated cAMP production (28, 29) and
β-arrestin recruitment to the receptor (29, 30). Due to the high
signal amplification of the G-protein activation assay compared
with β-arrestin recruitment, to achieve comparable signaling
outputs between the two, we used endogenously expressed β2AR
in the reporter cells to measure cAMP production, but we used
stably overexpressed β2V2R for monitoring β-arrestin recruit-
ment. The β2V2R, a chimeric receptor with a V2R tail at the C
terminus, displays stronger and more stable agonist-promoted
β-arrestin binding than the native β2AR while retaining the
pharmacological properties of the native β2AR (31). Compound
15 decreased the isoproterenol-stimulated responses in both
assays (Fig. 3 A and B). We observed rightward shifts of the EC50
values, as well as decreases in the maximal level of the stimulated
responses in the presence of increasing concentrations of 15, indi-
cating that 15 inhibits β2AR agonist-induced functional responses.
Additionally, the extent of rightward shift of isoproterenol potency
promoted by 15 was similar for both G-protein activation and
β-arrestin recruitment to activated receptor. On the other hand, the
decreases in the maximal response induced by 15 were more robust
in β-arrestin recruitment than in cAMP production (Fig. 3 A and B).
This likely is attributed to the differences in the sensitivity between
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Fig. 2. Characterization of 15 for its binding to the β2AR. (A) Dose–response curves of isoproterenol (ISO) competition binding to the β2AR reconstituted
in nanodiscs with 125I-CYP were obtained in the presence of various concentrations of 15 as indicated. Values were expressed as percentages of the maximal
125I-CYP binding level obtained from a one-site competition binding-log IC50 curve fit of the vehicle [0.9% dimethyl sulfoxide (DMSO)] control data. Points on
curves represent mean ± SEM obtained from at least three independent experiments done in duplicate. (B) The half-maximal concentration of 15 in the
changes of isoproterenol competition binding was obtained from a dose–response curve replotted with the data set at 0.1 μM isoproterenol with various
doses of 15 in A. (C) Dose-dependent increases in inverse agonist 3H-ICI-118,551 (ICI) binding to the β2AR in nanodiscs. Points on the curve represent nor-
malized values as percentages of the 3H-ICI-118,551 binding amount in the absence of 15 and mean ± SEM obtained from at least four independent ex-
periments done in duplicate. (D) Characteristics of 15 for its physical interaction with the β2AR were determined by the isothermal titration calorimetry (ITC)
analysis with the detergent-solubilized, purified receptor. The thermogram (Top) and binding isotherm with the best titration curve fit (Bottom) shown are
representatives of three independent experiments. Values represent mean ± SEM. (E) Extent of nanobody-60 (Nb60) binding to the β2AR determined by ELISA
in the presence of different ligands including 15. Values were expressed as ratios of the level of Nb60 binding in the vehicle (0.5% DMSO) control sample and
represent mean ± SEM obtained from three independent experiments done in duplicate. BI, BI-167107. (F) The levels of 3H-Fen binding to the β2AR upon
treatment with the vehicle control (0.5% DMSO) or 15 at 50 μM in the absence or presence of transducers, either trimeric Gαβγ protein or β-arrestin1 (β-arr1)
together with Fab30. Values were expressed as fold changes of the level of 3H-Fen binding in the vehicle (DMSO) control sample without the transducer and
represent mean ± SEM obtained from three independent experiments done in duplicate. (G) Compound 15 dose-dependent decreases in the level of 3H-Fen
high-affinity binding to the β2AR promoted by either Gαβγ protein or β-arr1 together with Fab30. Values were expressed as percentages of the maximal
3H-Fen binding level promoted by each transducer in the vehicle control (0.5% DMSO) and represent mean ± SEM obtained from at least three independent
experiments done in duplicate. All of the statistical analyses in the figure were performed, as described in Materials and Methods.
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Fig. 3. The effect of 15 on β2AR-mediated functional activities. After pre-
treatment with 15 for 20 min at various concentrations as indicated, the
β2AR-mediated activities in cells were measured upon stimulation with iso-
proterenol (ISO) in a dose-dependent manner: (A) cAMP production by the
endogenously expressed β2AR and (B) β-arrestin recruitment to the exoge-
nously expressed β2V2R. Values were expressed as percentages of the max-
imal level of the isoproterenol-induced activity in the vehicle (0.5% DMSO)
control. Points on curves represent mean ± SEM obtained from four inde-
pendent experiments done in duplicate. All of the statistical analyses in the
figure were performed as described in Materials and Methods.
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the assays, as described before (29), rather than to any biased ac-
tivity of 15. Such unbiased inhibition of β2AR activity by 15 is
consistent with the finding that 15 similarly inhibits the high-affinity
binding of 3H-Fen promoted by either transducer (G protein or
β-arrestin) (Fig. 2G). These results confirm that 15modulates β2AR
by antagonizing its agonist-induced activity.
We further validated that the inhibitory effect of 15 in functional
assays was a result of specific inhibition at the receptor level and not
due to nonspecific effects by testing 15 in other cell-based assays
that have distinct readouts from the luminescence-based assays
shown in Fig. 3. We monitored the effect of 15 on cAMP pro-
duction upon stimulation of the overexpressed β2AR using a
fluorescence resonance energy transfer (FRET)-based biosensor,
ICUE2 (32). In this experiment, 15 caused a rightward shift in the
EC50 for isoproterenol-stimulated cAMP production (Fig. S2A),
consistent with that shown in Fig. 3A, albeit without changing the
maximal response. This may be attributed to the increased am-
plification of the signal due to overexpression of the β2AR in this
assay compared with the signal by the receptor expressed at en-
dogenous levels in Fig. 3A. Similarly, we also confirmed the in-
hibitory effect of 15 on agonist-stimulated β-arrestin recruitment
to the β2AR by assessing FRET signals between β2AR-YFP and
CFP-β-arrestin2 (Fig. S2B). We further confirmed the inhibitory
effect of 15 on β2AR activation using an in vitro GTPase activity
assay with the β2AR reconstituted into HDL particles together
with purified Gs protein (Fig. S2C). The 15-induced shift in the
EC50 for isoproterenol obtained in this in vitro assay is comparable
to that observed in the cell-based assays, suggesting that 15 must
readily penetrate cell membranes to bind to an intracellular region
of the β2AR, which is suggested by the result in Fig. 2E.
Selective Inhibition of β2AR-Mediated Activities by Compound 15. To
confirm the selectivity of 15 for the β2AR, we performed func-
tional assays to evaluate whether 15 inhibited activation of other
members of the GPCR family closely or distantly related to the
β2AR. First, we compared the extent of 15 blockade of agonist-
stimulated activities of β2AR with two other endogenously
expressed Gs-coupled receptors in HEK-293 cells, the prosta-
glandin E2 (PGE2) and vasoactive intestinal peptide (VIP) re-
ceptors. Notably, 15 had no effect on cAMP production following
stimulation of these receptors (Fig. S3 A and B). Additionally, we
looked at the specificity of 15 for the β2AR by assessing its in-
hibitory effect on β-arrestin recruitment to other receptors besides
the chimeric β2AR (β2V2R). Here, we used the parental cell line
stably expressing β-arrestin2 alone, and transiently expressed re-
ceptors indicated in Fig. 4. First, we confirmed that the extent of
15-mediated inhibition of agonist-stimulated β-arrestin recruitment to
the wild-type β2AR (Fig. 4A) is comparable to that obtained in the
transiently expressed chimeric receptor, β2V2R (Fig. 4B). On the
other hand, following stimulation of the β1AR, a receptor closely
related to the β2AR, 15 substantially inhibited the maximal response
as well as the basal activity in a concentration-dependent manner,
whereas no significant changes were observed in the EC50 value (Fig.
4C). We also observed significant, but much reduced, inhibitory ef-
fects of 15 on β-arrestin recruitment to the vasopressin V2 receptor
(V2R), which is also a Gs-coupled receptor (Fig. 4D). In contrast to
this, 15 only minimally inhibited agonist-induced β-arrestin recruit-
ment to the VIPR, another Gs-coupled receptor. We observed only
minimal decreases in the maximal response to stimulation with VIP
without any change in the EC50 value induced by 15 (Fig. 4E), con-
sistent with the result obtained in cAMP accumulation (Fig. S3B).
Furthermore, no significant inhibition by 15 was detected in β-arrestin
recruitment to the Gq-coupled angiotensin II type 1 receptor (AT1R)
(Fig. 4F). To further assess the extent of the 15 inhibitory activities
among different receptors, we quantified the level of 15-mediated
decreases in the maximal response as well as shifts of the EC50 value
exhibited as fold shifts (Table S2). These results demonstrate that the
inhibitory effect of 15 on agonist-stimulated responses is greatest for
the β2AR and is substantially diminished in even closely related re-
ceptors such as β1AR.
To obtain further insights into the specificity of 15 for the
β2AR, we examined its inhibitory activity on agonist-induced
β-arrestin internalization. Unlike “class B” receptors, including
the V2R and the AT1R whose tight interactions with β-arrestin
allow for their cointernalization, “class A” receptors such as the
β2AR have weaker β-arrestin interactions and are not cointer-
nalized with β-arrestin (33). Therefore, we examined the effect of
15 on this functional activity with the transiently expressed
β2V2R (Fig. S4A), V2R (Fig. S4B), and AT1R (Fig. S4C). The
extent of β-arrestin internalization was monitored by measuring
the amount of β-arrestin targeted to endosomes (34). Results
obtained in this assay are consistent with the inhibitory effects of
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Fig. 4. Specificity of 15 inhibition for β2AR-mediated activity. Various receptors were transiently expressed to monitor β-arrestin recruitment, including (A)
β2AR, (B) β2V2R, (C) β1AR, (D) V2R, (E) VIPR, and (F) AT1R. After pretreatment with 15 at different concentrations as indicated for 20 min, the extent of agonist-
induced β-arrestin recruitment to these receptors was determined in a dose-dependent manner. Values were expressed as percentages of the maximal level of
the activity induced by the agonist of each receptor in the vehicle (0.5% DMSO) control. Points on graphs represent mean ± SEM obtained from at least three
independent experiments done in duplicate. AngII, angiotensin II; AVP, arginine vasopressin; ISO, isoproterenol; VIP, vasoactive intestinal peptide.
Ahn et al. PNAS | February 14, 2017 | vol. 114 | no. 7 | 1711
PH
A
RM
A
CO
LO
G
Y
15 on β-arrestin recruitment to activated receptors as shown in
Fig. 4, which are summarized in Table S2, further confirming the
specificity of the modulating activity of 15 for the β2AR.
We also investigated whether the NAM activity of 15 at the
β2AR was dependent on the presence of a specific agonist at the
orthosteric site (i.e., probe dependence). We performed this by
monitoring Gs-mediated cAMP production and β-arrestin re-
cruitment to the receptor in the presence of orthosteric probes
ranging from full to weak partial agonists, including epinephrine,
fenoterol, and clenbuterol (Fig. S5) as done with isoproterenol
(Fig. 3). We also compared competition binding of these agonists
to the β2AR with 125I-CYP in the presence of different con-
centrations of 15 (Fig. 2A and Fig. S5), which allowed us to as-
sess the probe dependence of 15 among the agonists in the
absence of transducer coupling. Table S3 shows the summary of
quantified values in each assay, including the extent of 15-mediated
decreases in the maximal response and shifts of the EC50 value
exhibited as fold shifts. Overall, 15 appears to display no sig-
nificant probe dependence among the tested agonists. We ob-
served that the extent of the EC50 value shift by 15, which is
consistent among the tested assays, follows the efficacy of the
tested agonists. On the other hand, the magnitude of 15 in-
hibition of the maximal response is negatively correlated with
the efficacy of these agonists.
Structure–Activity Relationships of Compound 15 Analogs at the β2AR.
To discern the structure–activity relationship (SAR) pattern for the
allosteric modulation of 15 at the β2AR, we designed and synthe-
sized a series of 15 derivatives (Table S4). We assessed the ability of
these derivatives to modulate β2AR functions in two different types
of experimental settings. These were cell-based activity assays, in-
cluding G-protein–mediated cAMP production and β-arrestin re-
cruitment to the activated β2AR, as well as high-affinity binding of
the agonist 3H-Fen to the receptor induced by transducers, Gs or
β-arrestin. To assist our SAR analyses, 15 was divided into three
structural subunits, the methylbenzamide (region I), bromo-benzyl
(region II), and cyclohexylmethyl-benzene (region III) regions, into
each of which we introduced modifications. We found that the
formamide group in region I (methylbenzamide) is an important
determinant of functional properties of 15. Removal of this group
on the phenyl ring (A1) led to a dramatic decrease in the inhibitory
activity of 15 down to about 20% or less of its original activity. The
same, but less severe, trend was observed when the position of this
formamide group was changed from its original para-position to a
meta-position (A2), which resulted in a ∼60% reduction of its
original activity. In the case of region II (bromo-benzyl), removal of
the electronegative atom bromine (A3) also caused variable but
substantial attenuation of the inhibitory activity of 15 down to about
10–55%. Two other modifications in this region, replacement of
bromine with fluorine, an atom of comparable electronegativity but
smaller radius (A4), and introduction of additional bromine at the
meta-position of the phenyl ring (A5) modestly decreased the
functional effects of 15. Next, we evaluated the activity of deriv-
atives with modifications on the aromatic ring in region III
(cyclohexylmethyl-benzene). Interestingly, addition of a hydroxyl
group to this ring at the para-position (A6) led to dramatic loss of
inhibitory activity, while replacing the hydroxyl group at this po-
sition with a slightly hydrophobic methoxy group (A7) partially
restored the inhibitory activity. This strongly suggests that the
hydrophobic nature of this region is another important determi-
nant for efficient interaction of 15 with the presumably hydro-
phobic portion of the putative binding site of 15 on the β2AR.
Discussion
We report here the discovery and characterization of a small
molecule, compound 15, as an allosteric β-blocker. Compound
15 was derived from an in vitro affinity-based screening of DELs
against the purified human β2AR. Compound 15 shares no
structural or chemical similarities with known β2AR orthosteric
ligands, and it does not compete with radiolabeled β2AR ligands
for binding at the orthosteric site. On the other hand, it binds
allosterically to the β2AR with low micromolar affinity. The
compound negatively modulates the binding of agonists to the
β2AR while it clearly displays positive cooperativity with an
orthosteric inverse agonist. In addition, in cell-based functional
assays, 15 displays robust inhibition of β2AR agonist-promoted,
Gs-mediated cAMP generation as well as β-arrestin recruitment
to the receptor. Together, these characteristics demonstrate that
15 allosterically binds to and stabilizes an inactive conformation
of the β2AR, which are the classic hallmarks of a negative allo-
steric modulator (5, 35).
A large number of orthosteric ligands for the β2AR have been
developed, whereas before this study, no allosteric small-molecule
β2AR ligand had been identified. The affinity-based screening
strategy is an ideal way to identify allosteric ligands for a receptor,
and DEL screening is an innovative strategy to perform affinity-
based selections against targets that are isolated or expressed on
whole cells (12). Although this technique enables an unprecedented
increase in the size of libraries that can be screened compared with
conventional activity-based screening formats, its use has mostly
been limited to soluble protein targets (12, 13). Due to the inherent
difficulty in isolating functional membrane proteins, this technique
has been only rarely used to obtain ligands for GPCRs. To date,
there has been only one report describing the discovery of a ligand
for a GPCR from a DEL (16). There, the recombinant NK3
tachykinin receptor expressed on HEK-293 cells was used as a
target in a whole-cell selection format to identify an inhibitor for the
receptor (16). Here, we have demonstrated that the DEL screening
strategy can be successfully applied to the isolation of small-molecule
ligands using a purified GPCR. Although our study was focused
on isolating and characterizing β2AR allosteric ligands, this strat-
egy could be used as well to isolate ligands that target orthosteric
sites of GPCRs. Despite the power of this approach, predicting the
functional outcomes of the isolated compounds remains empirical.
However, in our in vitro purified receptor target system, it is highly
feasible to bias the selections through differential display of the
receptor in unique conformations (e.g., agonist vs. antagonist vs.
no ligand in the orthosteric site) or in complex with signaling
partners such as G proteins or β-arrestins. This should provide
allosteric modulators with distinct properties (e.g., NAMs, PAMs,
or even biased molecules for coupling to transducers, leading to
signaling bias).
To date, pharmacological studies of GPCR allosteric modu-
lation have been restricted to a few receptor families including
muscarinic acetylcholine, adenosine, chemokine, and metabo-
tropic glutamate receptors (5, 36). Compared with orthosteric
ligands, drugs targeting allosteric sites often display greater re-
ceptor subtype selectivity and therefore potentially reduce ad-
verse side effects (4, 5). This is presumably due to decreased
evolutionary pressure at allosteric sites than at the orthosteric
site of GPCRs (35), leading to their greater divergence within a
family. Moreover, multiple allosteric sites can exist on a given
receptor (37). In addition, allosteric GPCR modulators may have
greater potential than orthosteric ligands to engender biased
signaling through selective modulation of specific signaling path-
ways, for example, G-protein versus β-arrestin pathways (4).
Our SAR studies provide insights into key regions of 15 that must
engage in contacts with the allosteric binding site on the β2AR to
allow its functional modulation. We found some alterations, including
complete deletions of the formamide group in region I and bromine
in region II, lead to dramatic decreases in the functional activities of
the parent compound, 15. We also observed a positive association
between increased polarity of region III and loss of functional activity.
This suggests that this region of the molecule might interface deep
within the β2AR allosteric site to establish contacts with core
hydrophobic residues.
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As with other GPCRs, several putative allosteric sites on the
β2AR have been recently proposed based on crystal structures
(37). Some are located at the intracellular face of the receptor;
these are relatively large and can accommodate a wide range of
compound sizes. Interestingly, most of the currently reported non–
small-molecule β2AR allosteric modulators, such as nanobodies
(10, 22, 38) and RNA aptamers (11), bind to intracellular cavities
that overlap with the G-protein binding site (39). This appears to
be true as well for 15 because it competes for β2AR binding with a
nanobody (Nb60) that favors an inactive conformation and that
binds to this intracellular region of the β2AR (22). Although our
findings suggest that 15 binds to the intracellular region of the
β2AR, further SAR and structural studies at atomic-level resolu-
tion will be required to precisely define the site and mechanism of
action, by which 15 acts as a NAM.
In summary, our study reports the discovery via in vitro affinity
selection of a DEL against purified receptors and functional
characterization of a β2AR-selective negative allosteric modu-
lator. Our findings suggest that targeting GPCR allosteric sites
with such combinatorial small-molecule libraries provides a
powerful and efficient approach for developing highly selective
ligands that can modulate a wide range of receptor’s functional
activities. Furthermore, our findings establish a proof-of-concept
strategy using the DEL screening technique, which can be broadly
applied to discover small molecules for other GPCRs.
Materials and Methods
Complete details and descriptions of the materials used; cell culture and
transfections; expression and purification of the β2AR; purified β2AR-based DEL
selection, quantitative PCR, and next-generation sequencing analysis; recon-
stitution of the β2AR into HDL particles; radioligand binding; ITC; ELISA;
measurement of cAMP accumulation and in vitro GTPase activity; β-arrestin
recruitment and β-arrestin endocytosis assays; data analyses; and synthesis and
characterization of compounds are provided in SI Materials and Methods.
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